Want to see AU:EMD full AI Analyst Report?
EMD Stock Chart & Stats
AU$0.06
>-AU$0.01(-2.94%)
At close: 4:00 PM EST
AU$0.06
>-AU$0.01(-2.94%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.08
Previous CloseN/A
Volume148.47K
Average Volume (3M)4.06M
Market Cap
AU$32.26M
Enterprise ValueAU$14.04M
Total Cash (Recent Filing)AU$10.50M
Total Debt (Recent Filing)AU$1.06M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding806,561,040
10 Day Avg. Volume2,903,931
30 Day Avg. Volume4,056,978
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.37
Price to Sales (P/S)9.01
P/FCF Ratio-4.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$20.30M
Bulls Say, Bears Say
Bulls Say
Manageable Leverage And Relatively Healthy Equity FinancingLow debt (debt-to-equity 0.12) and a relatively healthy equity ratio provide durable financial flexibility. This reduces refinancing and solvency risk, allowing the company to fund clinical programs and trials over months without immediate high interest burdens, supporting strategic continuity.
Service-based Revenue Model With Clinical OperationsA fee-for-service clinical model plus contracted clinical-trial services creates recurring, less capital-intensive cash generation potential versus product commercialization. This business mix supports steady demand for mental-health services and monetizes clinical expertise over time, aiding sustainable revenue streams.
Clinical Research Capability And Focus On Novel TherapiesHaving in-house clinical research and a focus on emerging areas like psychedelic-assisted therapies offers structural upside: access to research funding, potential partnerships, and proprietary clinical validation. This strengthens differentiation and long-term optionality beyond routine clinical services.
Bears Say
Revenue Decline And Negative Profitability Across MarginsA 21% revenue decline coupled with negative gross, EBIT/EBITDA and net margins points to structural demand or operating issues. Persistent top-line contraction and unprofitable operations limit reinvestment in clinical programs and prolong reliance on external funding for growth initiatives.
Negative Operating And Free Cash FlowsSustained negative operating and free cash flows reduce runway and heighten dependence on capital raises. For a clinical-services and research business, cash deficits constrain trial funding, hiring and scaling, elevating execution risk over the next several months unless cash generation improves.
Negative Return On Equity And Weak Returns To ShareholdersNegative ROE signals the business is not generating adequate returns on capital, reflecting operational inefficiency or poor margin structure. Over months this hampers ability to attract capital on favorable terms and undermines the economics of scaling clinical and research activities without structural improvements.
Emyria Ltd News
EMD FAQ
What was Emyria Ltd’s price range in the past 12 months?
Emyria Ltd lowest share price was AU$0.03 and its highest was AU$0.08 in the past 12 months.
What is Emyria Ltd’s market cap?
Emyria Ltd’s market cap is AU$32.26M.
When is Emyria Ltd’s upcoming earnings report date?
Emyria Ltd’s upcoming earnings report date is Sep 01, 2026 which is in 52 days.
How were Emyria Ltd’s earnings last quarter?
Emyria Ltd released its earnings results on Feb 26, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Emyria Ltd overvalued?
According to Wall Street analysts Emyria Ltd’s price is currently Overvalued.
Does Emyria Ltd pay dividends?
Emyria Ltd does not currently pay dividends.
What is Emyria Ltd’s EPS estimate?
Emyria Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emyria Ltd have?
Emyria Ltd has 806,561,040 shares outstanding.
What happened to Emyria Ltd’s price movement after its last earnings report?
Emyria Ltd reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.704%.
Which hedge fund is a major shareholder of Emyria Ltd?
Currently, no hedge funds are holding shares in AU:EMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Emyria Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.66%
12-Months-Change
Fundamentals
Return on Equity
-52.26%
Trailing 12-Months
Asset Growth
170.82%
Trailing 12-Months
Company Description
Emyria Ltd
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceuticals, alongside an initiative for discovering new MDMA-based drugs. Among its pipeline, EMD-RX5 is being explored for psychological distress and irritable bowel syndrome, while EMD-RX7 targets a variety of medical conditions. Established in 2018 and based in Leederville, Australia, the company adopted its current name, Emyria Limited, in September 2020, having previously operated as Emerald Clinics Limited.
Technical Analysis
Cogstate Ltd
―
Oneview Healthcare Chess Depository Interests repr 1
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
Doctor Care Anywhere Group PLC Shs Chess Depository Interests Repr 1 sh
―
Options Prices
Currently, No data available
---